Sulbactam–durlobactam and cefiderocol combination treatment of Burkholderia cenocepacia -associated Fitz–Hugh–Curtis syndrome

Antimicrobial Agents and Chemotherapy 2026 Open access

Read full text
Authors: Bhavita Gaglani, Tessa M Andermann, Claire Wate, Jorge Oldan, Chirag Sureshchandra Desai, Steven H. Marshall, Robert A. Bonomo, Ray Coakley, David van Duin, A M Lachiewicz
DOI: 10.1128/aac.01542-25
Cited by: 1
References: 19

Abstract

ABSTRACT A 50-year-old woman with cystic fibrosis (CF) and lung transplantation developed persistent deep abscesses due to multidrug-resistant (MDR) Burkholderia cenocepacia, unresponsive to multiple antibiotics and surgeries. Combination therapy with sulbactam–durlobactam (SUL-DUR) and cefiderocol (FDC) along with surgical interventions led to clinical and radiographic stability. This report of a successful sulbactam–durlobactam and cefiderocol treatment highlights this targeted β-lactam-β-lactamase inhibitor combination as an option for refractory B. cepacia complex (BCC) infections.

Fields of Study & Subjects

Cystic Fibrosis Research Advances Immunodeficiency and Autoimmune Disorders Pneumocystis jirovecii pneumonia detection and treatment

Publication details

Journal / source
Antimicrobial Agents and Chemotherapy
Publisher
American Society for Microbiology
Volume
70
Issue
7
Pages
e0154225–e0154225
Publication date
30 April 2026
Language
EN